Oncimmune Holdings PLC Grant of Options and PDMR Dealing (4292F)
November 04 2022 - 12:16PM
UK Regulatory
TIDMONC
RNS Number : 4292F
Oncimmune Holdings PLC
04 November 2022
4 November 2022
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that on 3 November 2022,
options ("Options") to subscribe for an aggregate of 196,809
ordinary shares of GBP0.01 each in the Company ("Ordinary Shares")
were granted to Adam Hill (Chief Executive Officer), Matthew Hall
(Chief Financial Officer) and Ron Kirschner (General Counsel &
Company Secretary) as follows:
Name Position No. of Options Exercise
Awarded Price per
Share
Adam Hill Chief Executive Officer 125,000 GBP0.50
-------------------------- --------------- -----------
Matthew Hall Chief Financial Officer 30,000 GBP0.50
-------------------------- --------------- -----------
Ron Kirschner General Counsel & Company 30,000 GBP0.50
Secretary
-------------------------- --------------- -----------
The Options have been granted under the 2016 Share Option Plan,
have an exercise price of GBP0.50, being the closing price of
Ordinary Shares in Oncimmune Holdings plc on 2 November 2022, and
vest annually in five equal parts from the date of grant until the
fifth anniversary of grant.
Following this grant, each of Adam Hill, Matthew Hall and Ron
Kirschner hold the following interests in the Company:
Name Number of Ordinary Number of Options
Shares currently held post grant
held
Adam Hill 73,872 3,615,862
------------------- ------------------
Matthew Hall 11,935 809,554
------------------- ------------------
Ron Kirschner 1,652 556,738
------------------- ------------------
This announcement, including the notification below, is made in
accordance with the requirements of the UK Market Abuse Regulation
and serves as notification and public disclosure of transactions by
persons discharging managerial responsibilities ("PDMR") and
persons closely associated with them.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name 1. Adam Hill
2. Matthew Hall
3. Ron Kirschner
--------------------------------- ----------------------------------------------
Reason for the notification
2
---------------------------------------------------------------------------------
a) Position/status 1. Chief Executive Officer
2. Chief Financial Officer
3. General Counsel & Company Secretary
--------------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
--------------------------------- ----------------------------------------------
b) LEI 213800HCYIWT6YPI1I02
--------------------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------
a) Description Ordinary Shares of GBP0.01 each
of the financial
instrument,
type of instrument
Identification ISIN: GB00BYQ94H38
code
b) Nature of the Grant of options
transaction
--------------------------------- ----------------------------------------------
c) Price(s) and
volume(s)
----------------------- ------------------
Price(s) Volume(s)
----------------------- ------------------
1. GBP0.50 125,000
-------------------------------------------------------------- ------------------
2. GBP0.50 30,000
-------------------------------------------------------------- ------------------
3. GBP0.50 30,000
-------------------------------------------------------------- ------------------
d) Aggregated
information
- Aggregated N/A - single transaction
volume
- Price
e) Date of the 3 November 2022
transaction
--------------------------------- ----------------------------------------------
f) Place of the Outside a trading venue
transaction
--------------------------------- ----------------------------------------------
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
Media enquiries:
Freelands Finance
John Goold
IR@oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBKQBDABDDNDK
(END) Dow Jones Newswires
November 04, 2022 12:16 ET (16:16 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024